Selected publications
-
Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer.
Journal of Clinical Oncology.
2016
Review
GET IT
Times cited: 40 -
Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3.
Journal of Clinical Oncology.
2016
Conference Paper
GET IT
Times cited: 127 -
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.
Annals of Oncology.
2016
Academic Article
GET IT
Times cited: 27 -
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Expanded access in North America.
Prostate.
2015
Academic Article
GET IT
Times cited: 7 -
Metastatic large-cell neuroendocrine prostate carcinoma: Successful treatment with androgen deprivation therapy.
Clinical Genitourinary Cancer.
2014
Academic Article
GET IT
Times cited: 3 -
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomised trial.
The lancet oncology.
2012
Academic Article
GET IT
Times cited: 162 -
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
The lancet oncology.
2012
Academic Article
GET IT
Times cited: 601 -
Increased survival with enzalutamide in prostate cancer after chemotherapy.
New England Journal of Medicine.
2012
Academic Article
GET IT
Times cited: 1785 -
Abiraterone and increased survival in metastatic prostate cancer.
New England Journal of Medicine.
2011
Academic Article
GET IT
Times cited: 2102 -
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
Journal of the National Cancer Institute.
2005
Academic Article
GET IT
Times cited: 222